Preservation of immune response during chemotherapy regimens

Patent metadata

Field	Value
Publication number	US-11529352-B2
Application number	US-201916432244-A
Country	US
Kind code	B2
Filing date	Jun 5, 2019
Priority date	Dec 5, 2016
Publication date	Dec 20, 2022
Grant date	Dec 20, 2022

Abstract

The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.

First claim

What is claimed is:

1. A method of treating a human having cancer comprising administering to the human a therapeutic regimen comprising a) an induction phase and b) a maintenance phase,
a) the induction phase comprising:
i) administering to the human an effective amount of a selective Cyclin Dependent Kinase 4/6 (CDK4/6) inhibitor of structure:

or a pharmaceutically acceptable salt thereof,
ii) administering to the human an effective amount of a chemotherapeutic agent, and
iii) administering to the human an effective amount of an immune checkpoint inhibitor,

wherein, during the induction phase, the CDK4/6 inhibitor is only administered 24 hours or less prior to the administration of the chemotherapeutic agent, and
wherein the chemotherapeutic agent is cytotoxic to immune effector cells;
b) the maintenance phase comprising:
i) administering to the human at least one dose of an effective amount of the immune checkpoint inhibitor, and

wherein the maintenance phase is administered following the cessation of the induction phase.

2. The method of claim 1 wherein the immune checkpoint inhibitor is selected from the group consisting of a Programmed Cell Death-1 (PD-1) inhibitor, a Programmed Cell Death-Ligand 1 (PD-L1) inhibitor, and a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor.

3. The method of claim 2 , wherein the immune checkpoint inhibitor is a PD-L1 inhibitor.

4. The method of claim 3 , wherein the PD-L1 inhibitor is selected from the group consisting of atezolizumab, avelumab, and durvalumab.

5. The method of claim 2 , wherein the immune checkpoint inhibitor is a PD-1 inhibitor.

6. The method of claim 5 , wherein the PD-1 inhibitor is selected from the group consisting of nivolumab, pidilizumab, and pembrolizumab.

7. The method of claim 2 , wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor.

8. The method of claim 7 , wherein the CTLA-4 inhibitor is selected from the group consisting of ipilimumab and tremelimumab.

9. The method of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of a protein synthesis inhibitor, a DNA-damaging chemotherapeutic, an akylating agent, a topoisomerase inhibitor, an RNA synthesis inhibitor, a DNA complex binder, a thiolate alkylating agent, a guanine alkylating agent, a tubulin binder, a DNA polymerase inhibitor, an anticancer enzyme, a RAC1 inhibitor, a thymidylate synthase inhibitor, an oxazophosphorine compound, an integrin inhibitor, an antifolate, a folate antimetabolite, and a combination thereof.

10. The method of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of carboplatin, cisplatin, oxaliplatin, 5-fluorouracil, floxuridine, capecitabine, gemcitabine, mytomycin, cyclophosphamide, decarbazine, abraxane, ifosfamide, topotecan, irinotecan, docetaxel, temozolomide, paclitaxel, etoposide, pemetrexed, and a combination thereof.

11. The method of claim 1 , wherein, during the induction phase, the CDK4/6 inhibitor is only administered about 30 minutes or less prior to the administration of the chemotherapeutic agent.

12. The method of claim 1 , wherein the immune checkpoint inhibitor is administered to the subject every three weeks during the induction phase and maintenance phase.

13. The method of claim 1 , wherein the cancer is selected from the group consisting of small cell lung cancer, non-small cell lung cancer, triple negative breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, bladder cancer, gastroesophageal cancer, cholangiocarcinoma, cervical cancer, and soft tissue sarcoma.

14. A method of treating a human having small cell lung cancer comprising administering to the human a therapeutic regimen comprising a) an induction phase comprising a 21-day cycle and b) a maintenance phase comprising a 21-day cycle,
a) the induction phase comprising:
i) administering to the human an effective amount of a selective CDK4/6 inhibitor of structure:

or a pharmaceutically acceptable salt thereof, on day 1, day 2, and day 3 of the 21-day cycle,
ii) administering to the human an effective amount of carboplatin on day 1 of the 21-day cycle,
iii) administering to the human an effective amount of etoposide on day 1, day 2, and day 3 of the 21-day cycle, and
iv) administering to the human an effective amount of atezolizumab on day 1 of the 21-day cycle;

wherein, during the induction phase, the CDK4/6 inhibitor is only administered 24 hours or less prior to the administration of carboplatin and/or etoposide;
b) the maintenance phase comprising:
i) administering to the human an effective amount of atezolizumab on day 1 of the 21-day cycle,

wherein the maintenance phase is administered following the cessation of the induction phase.

15. The method of claim 14 , wherein, during the induction phase, the CDK4/6 inhibitor is only administered about 4 hours or less prior to administration of the carboplatin and/or etoposide.

16. The method of claim 14 , wherein, during the induction phase, the CDK4/6 inhibitor is only administered about 30 minutes or less prior to the administration of the carboplatin and/or etoposide.

17. The method of claim 14 , wherein the CDK4/6 inhibitor is administered intravenously at a dose of between about 220 and 260 mg/m 2 .

18. The method of claim 17 , wherein the CDK4/6 inhibitor is administered intravenously at a dose of about 240 mg/m 2 .

19. The method of claim 14 , wherein the carboplatin is administered intravenously at a dose that provides an AUC of about 5.

20. The method of claim 14 , wherein the etoposide is administered intravenously at a dose of about 100 mg/m 2 .

21. The method of claim 14 , wherein the atezolizumab is administered in a dose of about 1200 mg.

22. The method of claim 14 , wherein the induction phase is repeated at least 2 times.

23. The method of claim 14 , wherein the induction phase is repeated at least 3 times.

24. The method of claim 14 , wherein the induction phase is repeated at least 4 times.

25. The method of claim 14 , wherein the maintenance phase is repeated at least 2 times.

26. The method of claim 14 , wherein the maintenance phase is repeated at least 3 times.

27. The method of claim 14 , wherein the maintenance phase is repeated at least 4 times.

28. The method of claim 1 , wherein the maintenance phase further comprises administering to the subject an effective amount of the CDK 4/6 inhibitor.

29. The method of claim 13 , wherein the cancer is bladder cancer.

30. The method of claim 29 , wherein the immune checkpoint inhibitor is a PD-L1 inhibitor.

31. The method of claim 30 , wherein the PD-L1 inhibitor is selected from the group consisting of atezolizumab, avelumab, and durvalumab.

32. The method of claim 31 , wherein the PD-L1 inhibitor is avelumab.

33. The method of claim 29 , wherein the chemotherapeutic agent is selected from the group consisting of gemcitabine, carboplatin, cisplatin, and a combination thereof.

34. The method of claim 13 , wherein the cancer

Assignees

• G1 Therapeutics Inc

Inventors

• Sorrentino Jessica A
• Lai Anne Y
• Strum Jay C
• Roberts Patrick Joseph

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/555

  containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K31/513

  having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title